AMENDMENTS TO THE CLAIMS

1. (Currently amended) A composition for the sustained release of a biologically active polypeptide consisting essentially of: a biocompatible polylactide-co-glycolide polymer having dispersed therein a biologically active glucoregulatory polypeptide, a sugar and glycine.

2. (Currently amended) The composition of claim 1, wherein the ~~glucoregulatory~~ polypeptide is selected from GLP-1, GLP-2, exendin-3, exendin-4 or a combination thereof.

3. (Currently amended) The composition of claim 2, wherein the ~~biologically active~~ polypeptide is present from about 0.01% (w/w) to about 50% (w/w) of the total weight of the composition.

4. (Currently amended) The ~~sustained release~~ composition of claim 3, wherein the ~~biologically active~~ polypeptide is present in a range from about 0.1% (w/w) to about 30% (w/w) of the total weight of the composition.

5. (Currently amended) The composition of claim 4, wherein the polypeptide is present from about 0.1% (w/w) to about 10% (w/w) of the total weight of the ~~sustained release~~ composition.

6. (Currently amended) The composition of claim 5, wherein the polypeptide is present from about 0.5% (w/w) to about 5% (w/w) of the total weight of the ~~sustained release~~ composition.

7. (Currently amended) The composition of claim 1, wherein the sugar is present from about 0.01% (w/w) to about 50% w/w of the total weight of the ~~sustained release~~ composition.

8. (Currently amended) The composition of claim 7, wherein the sugar is present from about 0.01% (w/w) to about 10% w/w of the total weight of the ~~sustained release~~ composition.

9. (Currently amended) The composition of claim 8, wherein the sugar is present from about 0.01% (w/w) to about 5% w/w of the total weight of the ~~sustained release~~ composition.

10. (Previously presented) The composition of claim 1, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol or a combination thereof.

11. (Previously presented) The composition of claim 10, wherein the sugar is selected from sucrose, trehalose, mannitol and combinations thereof.

12. (Currently amended) The composition of claim 10 [[11]], wherein the sugar is a disaccharide.

13. (Currently amended) The ~~sustained release~~ composition of claim 12, wherein the disaccharide is sucrose, trehalose or a combination thereof.

14. (Currently amended) A composition for the sustained release of a biologically active polypeptide consisting essentially of: a biocompatible polymer having dispersed therein exendin-4, sucrose and glycine.

15. (Previously presented) The composition of claim 14, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

16. (Currently amended) The composition of claim 15, wherein the sucrose is present at a concentration from about 0.01% w/w to about 10% w/w of the total weight of the ~~sustained release~~ composition.

17. (Currently amended) The composition of claim 15, wherein the exendin-4 is present at a concentration of about 0.1% w/w to about 10% w/w of the total weight of the composition.

18. (Withdrawn) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 1.

19. (Withdrawn) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 14.